A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers.
Authors
Escudier, BFaivre, S
Van Cutsem, E
Germann, N
Pouget, J
Plummer, R
Vergote, I
Thistlethwaite, Fiona C
Bjarnason, G
Jones, R
Mackay, H
Edeline, J
Fartoux, L
Hirte, H
Oza, A
Affiliation
Oncology Department, Gustave-Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, FranceIssue Date
2017-08-10
Metadata
Show full item recordAbstract
Tasquinimod is a small molecule with immunomodulatory, anti-angiogenic, and anti-metastatic properties that targets the tumor microenvironment. This study aimed to obtain a clinical proof of concept that tasquinimod was active and tolerable in patients with advanced solid tumors.Citation
A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers. 2017 Target OncolJournal
Targeted OncologyDOI
10.1007/s11523-017-0525-2PubMed ID
28798986Type
ArticleLanguage
enISSN
1776-260Xae974a485f413a2113503eed53cd6c53
10.1007/s11523-017-0525-2
Scopus Count
Collections
Related articles
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
- Authors: Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A
- Issue date: 2011 Sep
- Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.
- Authors: Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, Lechuga MJ, Cheng AL
- Issue date: 2009 Aug
- SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
- Authors: Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS
- Issue date: 2015 Nov
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
- Authors: Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X, SHIVA investigators
- Issue date: 2015 Oct
- A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
- Authors: McNamara MG, Le LW, Horgan AM, Aspinall A, Burak KW, Dhani N, Chen E, Sinaei M, Lo G, Kim TK, Rogalla P, Bathe OF, Knox JJ
- Issue date: 2015 May 15